Abaloparatide
Aliases: Tymlos · PTHrP(1-34) analog
Last verified: 2026-09-23
The short version
A PTHrP(1–34) analogue — bone anabolic with less hypercalcemia than teriparatide; approved for high-risk postmenopausal osteoporosis.
Identity & type
- Molecular type
- analog
- Origin
- A PTHrP(1–34) analogue — bone anabolic with less hypercalcemia than teriparatide; approved for high-risk postmenopausal osteoporosis.
Mechanism of action
More selective PTH1R RG-conformation agonism → stronger anabolic vs resorptive balance.
Dosing & routes
Official / clinical context
Approved drug — indications, dosing and warnings are defined by the official label. 80 mcg SC daily, max 24 months.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
80 mcg SC daily, max 24 months. Tymlos: similar to teriparatide with slightly less hypercalcemia; hip and spine density gains in trials and practice.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Tymlos: similar to teriparatide with slightly less hypercalcemia; hip and spine density gains in trials and practice.
Protocol — official vs community
Official / label
Tymlos, for postmenopausal women with osteoporosis at high fracture risk: 80 mcg SC once daily. (Scattered additional approvals/labels exist by market.)
Duration: Maximum 24 months of lifetime use. ACTIVE trial: ~86% reduction in new vertebral fractures.
PTHrP(1–34) analogue engineered for a more anabolic-selective PTH1R conformation: comparable fracture efficacy to teriparatide with a milder hypercalcemia/hypercalciuria profile, but more palpitations.
Community (anecdotal)
Essentially mirrors the label (80 mcg SC daily) where it appears at all.
- Cycle:
- Community framing copies the teriparatide 'anabolic window' pattern.
- Break:
- The 24-month lifetime cap applies identically.
Community footprint is much smaller than teriparatide's; it surfaces mostly as the 'cleaner calcium profile' alternative in bone-density discussions.
Human evidence
ACTIVE trial: −86% vertebral fractures vs placebo (with follow-on therapy).
Preclinical evidence
The preclinical phase was completed and submitted to regulators as part of registration; pharmacology and toxicology details are part of the official label.
Known risks
- Hypercalciuria, dizziness, palpitations.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Real-world data outside controlled trials